chloral hydrate
Chloral is a chlorinated aldehyde that found extensive use, beginning in the 1940s, as a precursor in the production of the insecticide DDT and, to a lesser extent, of other insecticides and pharmaceuticals. This use of chloral has declined steadily since the 1960s, especially in those countries where the use of DDT has been restricted. Chloral is readily converted to chloral hydrate in the presence of water. Chloral hydrate is used as a sedative before medical procedures and to reduce anxiety related to withdrawal from drugs. Wider exposure to chloral hydrate occurs at microgram-per-liter levels in drinking water and swimming pools as a result of chlorination. Chloral hydrate is a well-established aneuploidogenic agent that also has some mutagenic activity. In human cells in vitro, chloral hydrate induced aneuploidy, micronuclei and gene mutations. Chloral hydrate clearly induced micronuclei in Chinese hamster cells, whereas findings in mouse lymphoma cells were conflicting. Induction of somatic mutation (but not sex-linked mutation) by chloral hydrate was demonstrated in insects. Chloral hydrate is metabolized in vivo to trichloroethanol, which is responsible for its physiological and psychological effects. The metabolite of chloral hydrate exerts its pharmacological properties via enhancing the GABA receptor complex and therefore is similar in action to benzodiazepines, nonbenzodiazepines, and barbiturates. In clinical studies, oral chloral hydrate appears to have a lower sedation failure rate when compared with oral promethazine for children undergoing pediatric neurodiagnostic procedures. The sedation failure was similar for other comparisons such as oral dexmedetomidine, oral hydroxyzine hydrochloride, and oral midazolam. When compared with intravenous pentobarbital and music therapy, oral chloral hydrate had a higher sedation failure rate. Compared to dexmedetomidine, chloral hydrate was associated with a higher risk of nausea and vomiting. — NCATS
Clinical trial activity
19 trials · 22 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2007 (NCT00949780)
Timeline
Indications
Studied for
- Anxiety Disorders · Phase 3
- Brain Diseases · Phase 3
- Brain Injuries, Traumatic · Phase 2
- Child · Phase 3
- Chloral Hydrate · Phase 4
- Deep Sedation · Phase 4
- Dementia · Phase 3
- Depression · Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Electroencephalography · Phase 3
- Epilepsy · Phase 3
- Healthy Volunteers · Phase 1/Phase 2
- Heart Diseases · Phase 4
- Procedural Sedation · Phase 4
- Psychophysiologic Disorders · Phase 3
- Schizophrenia · Phase 3
- Sleep Initiation and Maintenance Disorders · Phase 4
- Tomography · Phase 2
Mechanism of action
- Unspecified targetOTHER
Unknown
Chloral hydrate is converted to the active compound trichloroethanol by hepatic alcohol dehydrogenase. The agent interacts with various neurotransmitter-operated ion channels, thereby enhancing gamma-aminobutyric acid (GABA)-A receptor mediated chloride currents and inhibiting amino acid receptor-activated ion currents. In addition, chloral hydrate enhances the agonistic effects of glycine receptors, inhibits AMPA-induced calcium influx in cortical neurons, and facilitates 5-HT 3 receptor-mediated currents in ganglionic neurons. Overall, this results in a depressive effect on the central nervous system.
Chemistry & pharmacology
SMILES
ClC(Cl)(Cl)C=O- Mol. weight
- 147.388 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaChloral hydrate ↗
- NCATSFLI06WS32H ↗
- ChEMBLCHEMBL455917 ↗
- ChEMBLCHEMBL1231821 ↗
- NCATS418M5916WG ↗
Also known as
- 1,1,1-trichloro-2,2-dihydroxyethane
- 1,1,1-trichloro-2,2-dihydroxyethane
- 1,1,1-trichloro-2,2-ethanediol
- 1,1,1-trichloro-2,2-ethanediol
- 2,2,2-trichloro-1,1-ethanediol
- 2,2,2-trichloro-1,1-ethanediol
- chloraldurat
- chloralhydrat
- chloralhydrat
- chloral hydrate
- chloral hydrate
- chloral hydrate
- chloral hydrate
- chloral hydrate
- chloral hydrate
- chloral hydrate
- chloral hydrate
- chloral hydrate
- chloral hydrate
- chloral monohydrate
- chloral monohydrate
- chlorhydrate
- chlorhydrate
- hydrochloric acid
- hydrochloric acid
- hydrochloric acid
- hydrochloric acid
- hydrochloric acid
- hydrochloric acid
- hydrochloric acid
- noctec
- noctec
- nycoton
- phaldrone
- sk-chloral hydrate
- sk-chloral hydrate
- trichloracetaldehyd-hydrat
- trichloracetaldehyd-hydrat
- trichloroacetaldehyde hydrate
- trichloroacetaldehyde hydrate
- trichloroacetaldehyde hydrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06606899 | Phase 4 | Sep 30, 2024 | Ain Shams University |
| NCT06443632 | N/A | Jun 1, 2024 | Shandong University |
| NCT06053840 | Phase 4 | Sep 21, 2023 | Pharmanovia |
| NCT06389318 | N/A | Mar 26, 2023 | Benha University |
| NCT04820205 | N/A | May 1, 2021 | Seoul National University |
| NCT04822064 | N/A | May 1, 2021 | Seoul National University |
| NCT05492812 | N/A | Jan 1, 2021 | Suleyman Demirel University |
| NCT03242629 | N/A | Jan 31, 2017 | Sun Yat-Sen University |
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT02523144 | Phase 4 | Sep 1, 2014 | University of Cincinnati |
| NCT02239445 | Phase 4 | Sep 1, 2014 | Guangzhou Medical University |
| NCT02195661 | Phase 3 | Apr 1, 2014 | University of Cape Town |
| NCT01402596 | Phase 2 | Aug 1, 2011 | University of Sao Paulo |
| NCT01255904 | Phase 4 | Aug 1, 2011 | Baylor University |
| NCT01149226 | N/A | May 1, 2010 | Yonsei University |
| NCT01128270 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2010 | National Institutes of Health (NIH), University of Florida |
| NCT01083797 | Phase 3 | Dec 1, 2009 | Federal University of Minas Gerais, Santa Casa de Misericórdia de Belo Horizonte |
| NCT00464451 | Phase 2 | Aug 1, 2009 | Pfizer, University of Kansas, Wesley Medical Center |
| NCT00949780 | Phase 2 | Oct 1, 2007 | Pontificia Universidade Catolica de Sao Paulo |
Organizations
Research & Development (22)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seoul National University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Benha University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Federal University of Minas Gerais | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2010 |
| Pfizer | For profit | 1 | 0 | 1 | 2009 |
| Pharmanovia | For profit | 1 | 1 | 1 | 2023 |
| Pontificia Universidade Catolica de Sao Paulo | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Santa Casa de Misericórdia de Belo Horizonte | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Shandong University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Suleyman Demirel University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Cape Town | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Kansas | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Sao Paulo | Academic/Hospital | 1 | 1 | 1 | 2011 |